UC Davis Health Clinical Studies

An Experimental Combination Study of S1803, Daratumumab/rHuPh20 +/- Lenalidomide for Multiple Myeloma (MM)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is being done to answer the following questions: 1. Will adding the experimetnal drug daratumumab/rHuPH20 to the usual maintenance treatment help multiple myeloma patients survive longer? 2. For patients who have no evidence of multiple myeloma in their bone marrow, should maintenance therapy be stopped after 2 years? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your multiple myeloma. The usual approach is defined as care most people get for multiple myeloma. The usual approach for patients who are not in a study is treatment with an FDA approved multiple myeloma drug (such as lenalidomide) after stem cell transplant.

Drug study, Phase 3
Any, age 18 to 75 years old

A Study of Experimental Blinatumomab for Localized B Cell Lymphoblastic Lymphoma (B-LLy)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being asked to take part in this research study because you have been diagnosed with Standard Risk-High B-cell Lymphoblastic Leukemia (SR-High B-ALL). Taking part in this study is voluntary. You may choose not to be in this study. If you decide not to be in this study, you will not be penalized and you will not lose any benefits to which you are entitled. You will still receive medical care. The overall goal of this study is to: • Compare the effects, good and/or bad, of adding blinatumomab to standard chemotherapy in subjects with SR-High B-ALL to find out which is better. The treatment involves cancer fighting medicine called chemotherapy. You have already been receiving chemotherapy for the past month. The treatment may also include the investigational medicine blinatumomab. The treatment on this study takes about 2-2 ¼ years. It is divided into 5-7 phases, depending on the treatment plan you receive. All people who receive cancer treatment are at risk of having side effects. In addition to killing tumor cells, cancer chemotherapy can damage normal tissue and produce side effects. In this study you will get 1 of 2 treatment plans. The 2 treatment plans are called Arms C and D. The 2 treatment plans are the same except for whether or not you will get the investigational medicine blinatumomab. The rest of the treatment that is given is standard therapy for people with SR-High B-ALL. On this study, Arm C is standard therapy and Arm D uses the investigational medicine blinatumomab in addition to standard therapy.

Drug study, Phase 3
Any, age -1 to 31 years old

Experimental Nab-Paclitaxel and Durvalumab With or Without Neoantigen Vaccine for Metastatic Triple Negative Breast Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is being done to learn about the effects (good and bad) of using an individualized vaccine. It will be given along with a drug called durvalumab and standard chemotherapy. We are comparing these effects to the effects of using durvalumab and standard chemotherapy alone. We want to find out if the individualized vaccine is better or worse than the usual approach for your metastatic triple negative breast cancer. The usual approach is defined as care most people get for metastatic triple negative breast cancer.

Drug study, Phase 2
Any, age 18 years or older

A Study of Chemoradiation With or Without Experimental Atezolizumab For Limited Stage Small Cell Lung Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is being done to answer the following question: Can we lower the chance of small cell lung cancer growing or spreading by adding an experimental immunotherapy drug (atezolizumab) to the usual treatment for this type of cancer? We are doing this study to find out if this approach is better or worse than the usual approach for your type of cancer. The usual approach is defined as care most people get for small cell lung cancer. The usual approach for patients with limited-stage small cell lung cancer who are not in a study is treatment with chemotherapy and radiation therapy.

Radiation study, Phase [2,3]
Any, age 18 years or older
Loading